Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chloe Kent

Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.

Latest From Chloe Kent

Biocon Expands Into Middle East With Tabuk Partnership

Biocon is set to bolster its planned expansion into the MENA region through a partnership with Saudi firm Tabuk Pharmaceuticals, which will commercialize select Biocon generics in the Middle East.

Deals Strategy

Lupin Partners With Biomm To Launch Pegfilgrastim Biosimilar In Brazil

Indian pharma firm Lupin has partnered with Biomm to market its proposed Neulasta biosimilar in Brazil, as it comes to the end of a tumultuous 2021.

Biosimilars Deals

Sawai To Take Over Facilities Owned By Scandal-Hit Kobayashi Kako

Kobayashi Kako has agreed to transfer ownership of eight of its production, research and distribution facilities to Sawai, which will use them to expand the manufacturing of its own generics. Business was suspended at Kobayashi Kako for 116 days this year after the company’s manufacturing deficiencies were linked to two deaths.

Deals Generic Drugs

British Columbia Adds Insulins To Its Biosimilar Switching Policy

Patients taking Humalog and NovoRapid will have six months to switch to their biosimilar equivalents after British Columbia added the rapid-acting insulins to its biosimilar switching policy.

Biosimilars Policy

Off-Patent Industry Calls For Security Of Supply Legislation In EU

Medicines for Europe has urged the European Commission to enshrine security of supply considerations for essential medicines into legislation. Without these, it says, additional cost containment measures for off-patent medicines under consideration by member states could threaten access by making production unsustainable for manufacturers.

Supply Chain Generic Drugs

Henlius CEO Wenjie Zhang Takes Over Chairman Role

Henlius has reshuffled its C-suite, with chairman Qiyu Chen stepping down from the role to take up a position as non-executive director and CEO Wenjie Zhang poised to step into his shoes.

Executive Changes China
See All
UsernamePublicRestriction

Register